SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Greenlee RT, Hill-Harmon MD, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001; 51: 15-36.
  • 2
    Ihde DC, Minna JD. Non-small cell lung cancer. Part I: biology, diagnosis, and staging. Curr Probl Cancer. 1991; 15: 61-104.
  • 3
    Clinical practice guideline for the treatment of unresectable non-small cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1997; 15: 2996-3018.
  • 4
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ. 1995; 311: 899-909.
  • 5
    Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer. 1995; 71: 366-370.
  • 6
    Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer. 1989; 60: 764-766.
  • 7
    Cullen MH, Joshi R, Chetiyawardana AD, Woodroffe CM. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer. 1989; 58: 359-361.
  • 8
    Tummarello D, Graziano F, Isidori P, Cellorino R. Symptomatic, Stage IV, non-small cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol. 1995; 35: 249-253.
  • 9
    Bunn PA Jr., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998; 5: 1807-1100.
  • 10
    Belani CP, Natale RB, Lee JS, et al. Randomized Phase III trial comparing cisplatin-etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC) [abstract]. Pro Am Soc Clin Oncol. 1998; 17: 455a.
  • 11
    Kelly K, Crowley J, Bunn PA, et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group trial. J Clin Oncol. 2001; 19: 3210-3218.
  • 12
    Schiller JH, Harrington D, Sandler A, et al. A randomized Phase III of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 1a.
  • 13
    Gatzemeier U, Rosell R, Betticher D, et al. Randomized pan-European trial comparing paclitaxel/carboplatin versus paclitaxel/cisplatin in advanced non-small cell lung cancer [abstract]. Eur J Cancer. 1999; 35 (Suppl 4): 246.
  • 14
    Johnson DH, Zhu J, Schiller JH, et al. E 1594 – A randomized Phase III trial in metastatic non-small cell lung cancer (NSCLC) – outcome of PS 2 patients (pts): an Eastern Cooperative Group Trial (ECOG) [abstract]. Proc Am Soc Clin Oncol. 1999; 18; 461a.
  • 15
    Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985; 260: 14873-14878.
  • 16
    Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988; 48: 1722-1726.
  • 17
    Negoro S, Fukuoka M, Niitani H, et al. A Phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother. 1991; 18: 1013-1019.
  • 18
    Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst. 1991; 83: 1164-1168.
  • 19
    Nakai H, Fukuoka M, Furuse K, et al. An early Phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother. 1991; 18: 607-612.
  • 20
    Fukuoka M, Negoro S, Niitani H, et al. A Phase I study of weekly administration of CPT-11 in lung cancer. Jpn J Cancer Chemother. 1990; 17: 993-997.
  • 21
    Baker L, Khan R, Lynch T, et al. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Amer Soc Clin Oncol. 1997; 16: 461a.
  • 22
    Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol. 1994; 12: 90-96.
  • 23
    Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer. 1993; 68: 777-782.
  • 24
    Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol. 1992; 10: 1775-1780.
  • 25
    DeVore RF, Johnson DH, Crawford J, et al. Phase II trial of irinotecan plus cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol. 1999; 17: 2710-2720.
  • 26
    Komiya T, Fukuoka M, Negoro S, et al. Randomized Phase III trial compared cisplatin and irinotecan (CPT-11) versus cisplatin and vindesine (VDS-P) versus irinotecan alone (CPT) in patients with advanced non-small cell lung cancer (NSCLC) – the final report [abstract]. Lung Cancer. 2000; 29 (Suppl): 28.
  • 27
    Takiguchi Y, Nagao K, Nishiwaki A, et al. The final results of a randomized Phase III trial comparing irinotecan (CPT-11) and cisplatin (CDDP) with vindesine (VDS) and CDDP in advanced non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer. 2000; 29 (Suppl): 28.
  • 28
    Socinski MA, Sandler AB, Miller LL, et al: Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol. 2001; 19: 1078-1087.
  • 29
    Cockcroft DW, Gault MH. Predication of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-34.
  • 30
    Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7: 1748-1756.
  • 31
    Bleiberg H, Cvitkovic E. Characterization and clinical management of CPT-11 (irinotecan) induced adverse events: the European perspective. Eur J Cancer. 1996; 32A (Suppl 3): S18-S23.
  • 32
    Rivory LP. Irinotecan (CPT-11): a brief overview. Clin Exp Pharmacol Physiol. 1996; 23: 1000-1004.
  • 33
    WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva: World Health Organization, 1979.
  • 34
    Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol. 1986; 4: 14-22.
  • 35
    Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in Stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989; 7: 1602-1613.
  • 36
    Masumoto N, Nakano S, Esaki T, Fujishima H, Tatsumoto T, Niho Y. Inhibition of cis-diaminodichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer. 1995; 62: 70-75.
  • 37
    Fukuoka M, Kudoh S, Musuda N. Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines and xenografts in nude mice. Proc Am Assoc Cancer Res. 1992; 33: 226.
  • 38
    Pei X, Nakaniski Y, Takayama K, et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anti-Cancer Drugs. 1997; 8: 231-237.
  • 39
    Hainsworth JD, Burris HA III, Erland JB, et al. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma. Cancer. 1999; 85: 1269-1276.
  • 40
    Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA Jr. A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2000; 6: 3474-3479.
  • 41
    Hainsworth JD, Burris HA, Morrissey LH, et al. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a Phase II trial of the Minnie Pearl Cancer Research Network. Cancer J. 2000; 6: 151-156.
  • 42
    Fujita A, Takabatake H, Tagaki S, Sekine K. Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer. Oncology. 1999; 6: 301-307.
  • 43
    Fujita A, Takabatake H, Tagaki S, Sekine K. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with Stage IIIB/IV non-small cell lung cancer. Cancer Chemother Pharmacol. 2000; 45: 279-283.
  • 44
    Kiura K, Ueoka H, Eguchi K, et al. Phase I study of cisplatin, docetaxel and irinotecan for advanced non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer. 2000; 29 (Suppl 1): 45.
  • 45
    Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small cell lung cancer: interim analysis of a Phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 2000; 18: 1451-1457.
  • 46
    Bunn PA Jr., Kelly K. Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non-small cell lung cancer. Clin Lung Cancer. 2000; 2 (Suppl 1): S23-S28.